[Stock in Focus] Kanaph Therapeutics Surges 190% on First Day of KOSDAQ Listing
Kanaph Therapeutics, a new drug development company, is trading 190% above its IPO price on its first day listed on KOSDAQ. In early trading, the share price rose more than 200% compared to the IPO price.
As of 9:30 a.m. on March 16, Kanaph Therapeutics was trading at 58,300 won, up 191.5% (38,300 won) from its IPO price of 20,000 won. In early trading, the share price surged to 63,600 won, a 218% increase over the IPO price.
Kanaph Therapeutics was founded in February 2019 and specializes in new drug development. The company is currently developing innovative new drugs using human genome-based drug development technologies.
In particular, Kanaph Therapeutics aims to address unmet medical needs for patients with solid tumors through immuno-oncology drugs based on dual antibody technology targeting the tumor microenvironment and immune activation modulation, as well as next-generation ADC (antibody-drug conjugate) therapies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The capital raised through the IPO will be used for clinical trials of its joint R&D pipeline, expansion of new pipelines, strengthening R&D capabilities, and operating funds.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.